Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Burning Rock Biotech Ltd (BNR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: BNR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 25.35% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.05M USD | Price to earnings Ratio - | 1Y Target Price 4.03 |
Price to earnings Ratio - | 1Y Target Price 4.03 | ||
Volume (30-day avg) 54447 | Beta 0.74 | 52 Weeks Range 2.18 - 7.90 | Updated Date 06/19/2025 |
52 Weeks Range 2.18 - 7.90 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-06-03 | When - | Estimate - | Actual -0.1724 |
Profitability
Profit Margin -45.59% | Operating Margin (TTM) -11.41% |
Management Effectiveness
Return on Assets (TTM) -14.39% | Return on Equity (TTM) -37.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -23006761 | Price to Sales(TTM) 0.08 |
Enterprise Value -23006761 | Price to Sales(TTM) 0.08 | ||
Enterprise Value to Revenue 0.03 | Enterprise Value to EBITDA -0.17 | Shares Outstanding 9034110 | Shares Floating 48307975 |
Shares Outstanding 9034110 | Shares Floating 48307975 | ||
Percent Insiders 3.92 | Percent Institutions 59.79 |
Analyst Ratings
Rating 5 | Target Price 3.96 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Burning Rock Biotech Ltd
Company Overview
History and Background
Burning Rock Biotech Ltd. was founded in 2014. It focuses on precision oncology via next-generation sequencing (NGS)-based cancer therapy selection, minimal residual disease monitoring, and cancer early detection.
Core Business Areas
- Therapy Selection: NGS-based tests to identify genetic alterations in tumors to guide treatment decisions.
- Minimal Residual Disease (MRD) Monitoring: Monitoring for recurrence after treatment by detecting circulating tumor DNA (ctDNA).
- Early Cancer Detection: Developing multi-cancer early detection (MCED) tests.
Leadership and Structure
The leadership team consists of key executives in areas such as R&D, operations, and commercial strategy. The organizational structure includes departments for research, clinical development, commercial operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- OncoScreen Plus: NGS-based comprehensive genomic profiling test for therapy selection. Market share varies by region and test type. Competitors include Illumina and Foundation Medicine.
- Lung Plasma MRD: MRD test for lung cancer patients. Market share is still developing as MRD testing becomes more widespread. Competitors include Guardant Health.
Market Dynamics
Industry Overview
The precision oncology market is growing rapidly, driven by advances in NGS technology and the increasing use of personalized medicine. There is increasing demand from clinicians and patients for accurate and timely genomic information to guide cancer treatment and monitor for recurrence.
Positioning
Burning Rock Biotechu00a0Ltd is a key player in the Chinese NGS-based cancer testing market. Its competitive advantages include its strong presence in the Chinese market, its comprehensive test menu, and its focus on innovation.
Total Addressable Market (TAM)
The global market for NGS-based cancer diagnostics is estimated to reach tens of billions of dollars. Burning Rock Biotechu00a0Ltd is well-positioned to capture a significant share of this market, particularly in China.
Upturn SWOT Analysis
Strengths
- Strong presence in the Chinese market
- Comprehensive test menu
- Focus on innovation
- Established relationships with leading hospitals and physicians in China
Weaknesses
- Reliance on the Chinese market
- Relatively small scale compared to global players
- Regulatory uncertainty in China
- Susceptible to fluctuations in Chinese economy
Opportunities
- Expanding into new geographic markets
- Developing new tests and applications
- Forming strategic partnerships
- Adoption of liquid biopsy for early cancer detection.
Threats
- Increased competition
- Pricing pressures
- Regulatory changes
- Technological advancements from competitors.
Competitors and Market Share
Key Competitors
- ILMN
- TMO
- GH
Competitive Landscape
Burning Rock Biotech Ltd. faces competition from both domestic and international players. Key competitive factors include test accuracy, breadth of test menu, pricing, and market access.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth trends depend on financial metrics. Data unavailable
Future Projections: Future projections require financial analysts estimates. Data unavailable
Recent Initiatives: Recent Initiatives require financial analysts estimates. Data unavailable
Summary
Burning Rock Biotech has a strong footing in the Chinese market for precision oncology, but is susceptible to regulatory and economic changes within China. They are innovating in the genomic profiling and minimal residual disease monitoring fields. However, they face strong competition and relatively smaller scale. Further expansion and diversified geography will be key.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Information
- Industry Reports
- Financial News
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may vary. The AI rating is generated based on available information and may not reflect all factors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Burning Rock Biotech Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-06-12 | Founder, Chairman & CEO Mr. Yusheng Han | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 674 | Website https://www.brbiotech.com |
Full time employees 674 | Website https://www.brbiotech.com | ||
Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS) based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various cancer types, including pan-cancer, lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, and ovarian cancer. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples, and OncoCompass, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore, which assesses microsatellite loci related to MSI status and detects mutations in genes associated with gastrointestinal cancers. It also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of the key products. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.